iBio Reports Fiscal Third Quarter 2024 Financial Results and Provides Corporate Update



Strengthened cash position with investment by healthcare specialist investors
Expanding into cardio-metabolic space through AstralBio collaboration

BRYAN, Texas and SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) — iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today reported financial results for the third quarter ended March 31, 2024 and provided a corporate update.

“In our third fiscal quarter, we continued to advance toward our goal of becoming a leading antibody discovery company with a differentiated machine-learning platform,” said Dr. Martin Brenner, CEO and Chief Scientific Officer. “Along with our recent equity financing, we secured a transformative partnership with AstralBio to discover and develop novel antibodies to treat obesity and other cardiometabolic diseases, with a lead program focused on targeting the transforming growth factor beta (TGFb) superfamily for treating muscle wasting and obesity. Our enhanced financial position has permitted us to accelerate the AstralBio collaboration, and we’ve already begun recruiting for key positions to support the process of identifying new molecules that are expected to simultaneously expand and diversify our pipeline. We believe we are well-positioned to advance our internal pipeline priorities in immuno-oncology and cardiometabolics, and drive partnerships in new therapeutic areas.”

Fiscal Third Quarter 2024 & Recent Corporate Updates:

Entered into a securities purchase agreement for a fully subscribed private investment in public equity (“PIPE”) financing with several institutional investors and an accredited investor in March, and consummated the financing in April for gross proceeds of approximately $15.0M before deducting placement agent fees and offering expenses.
Entered into a collaboration with AstralBio, Inc. to provide an exclusive license in the cardiometabolic and obesity space. iBio will develop four targets of interest, with the Company having the rights to license up to three of these targets prior to entering the clinic.
In February, iBio …

Full story available on Benzinga.com


Leave a Reply

Your email address will not be published. Required fields are marked *